Ascelia Pharma AB (publ)

OM:ACE Stock Report

Market Cap: SEK 377.9m

Ascelia Pharma Management

Management criteria checks 2/4

Ascelia Pharma's CEO is Magnus Corfitzen, appointed in Jan 2014, has a tenure of 11.92 years. total yearly compensation is SEK5.10M, comprised of 43.7% salary and 56.3% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth SEK2.40M. The average tenure of the management team and the board of directors is 5.9 years and 8.9 years respectively.

Key information

Magnus Corfitzen

Chief executive officer

SEK 5.1m

Total compensation

CEO salary percentage43.66%
CEO tenure11.9yrs
CEO ownership0.6%
Management average tenure5.9yrs
Board average tenure8.9yrs

Recent management updates

Recent updates

Is Ascelia Pharma (STO:ACE) Using Too Much Debt?

Jul 22
Is Ascelia Pharma (STO:ACE) Using Too Much Debt?

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

Apr 16
Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

Is Ascelia Pharma (STO:ACE) Using Too Much Debt?

Mar 06
Is Ascelia Pharma (STO:ACE) Using Too Much Debt?

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Nov 09
Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

May 31
Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

May 11
Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Aug 05
Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Jan 24
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Aug 23
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

May 19
Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07
Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09
Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Magnus Corfitzen's remuneration changed compared to Ascelia Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-SEK 89m

Jun 30 2025n/an/a

-SEK 95m

Mar 31 2025n/an/a

-SEK 85m

Dec 31 2024SEK 5mSEK 2m

-SEK 80m

Sep 30 2024n/an/a

-SEK 62m

Jun 30 2024n/an/a

-SEK 62m

Mar 31 2024n/an/a

-SEK 89m

Dec 31 2023SEK 4mSEK 2m

-SEK 109m

Sep 30 2023n/an/a

-SEK 152m

Jun 30 2023n/an/a

-SEK 157m

Mar 31 2023n/an/a

-SEK 139m

Dec 31 2022SEK 5mSEK 2m

-SEK 131m

Sep 30 2022n/an/a

-SEK 113m

Jun 30 2022n/an/a

-SEK 115m

Mar 31 2022n/an/a

-SEK 126m

Dec 31 2021SEK 15mSEK 2m

-SEK 126m

Sep 30 2021n/an/a

-SEK 127m

Jun 30 2021n/an/a

-SEK 113m

Mar 31 2021n/an/a

-SEK 111m

Dec 31 2020SEK 5mSEK 2m

-SEK 99m

Sep 30 2020n/an/a

-SEK 90m

Jun 30 2020n/an/a

-SEK 88m

Mar 31 2020n/an/a

-SEK 71m

Dec 31 2019SEK 3mSEK 992k

-SEK 66m

Compensation vs Market: Magnus's total compensation ($USD545.93K) is above average for companies of similar size in the Swedish market ($USD302.53K).

Compensation vs Earnings: Magnus's compensation has increased whilst the company is unprofitable.

CEO

Magnus Corfitzen (50 yo)

11.9yrs
Tenure
SEK 5,096,000
Compensation

Mr. Magnus O. Corfitzen serves as the Chief Executive Officer at Ascelia Pharma AB since 2014. He serves as a Director of NsGene A/S. He serves as a Director of DentoFit A/S.Mr. Corfitzen serves on the bo...

Leadership Team

NamePositionTenureCompensationOwnership
Magnus Corfitzen
Chief Executive Officer11.9yrsSEK 5.10m0.64%
SEK 2.4m
Jennie Wilborgsson
Chief Operating Officerless than a yearno data0.074%
SEK 280.5k
Andreas Norlin
Chief Scientific Officer3.2yrsno data0.11%
SEK 406.5k
Mikael Widell
Head of IR & Communications7.9yrsno datano data
Julie Brogren
Deputy CEO & Chief Commercial Officer5.9yrsno data0.28%
SEK 1.1m
5.9yrs
Average Tenure
54yo
Average Age

Experienced Management: ACE's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Benson
Independent Chairman of the Board of Directors8.9yrsSEK 550.00k0.20%
SEK 744.6k
Hans Maier
Independent Director8.9yrsSEK 263.00k0.016%
SEK 59.6k
Lauren Barnes
Independent Director5.6yrsSEK 273.00kno data
Helena Wennerström
Independent Director8.9yrsSEK 363.00k0.070%
SEK 265.8k
Marianne Kock
Independent Director1.2yrsSEK 48.00kno data
8.9yrs
Average Tenure
70yo
Average Age

Experienced Board: ACE's board of directors are considered experienced (8.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/10 19:05
End of Day Share Price 2025/12/10 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascelia Pharma AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier Sponsored
Lars HevrengDanske Bank
Maria Karlsson OsipovaDNB Carnegie Commissioned Research